Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762528 | 1.00 | CES2 (0.42) | CES2CES1PTGS1PTGS2ACKR3 | |
| SCHEMBL3776421 | 0.88 | CES2 (0.40) | CES2CES1PTGS1PTGS2ACKR3 | |
| SCHEMBL3776425 | 0.88 | CES2 (0.40) | CES2CES1PTGS1PTGS2ACKR3 | |
| SCHEMBL3768849 | 0.86 | CES2 (0.39) | CES2CES1PTGS1PTGS2ACKR3 | |
| SCHEMBL3768846 | 0.86 | CES2 (0.39) | CES2CES1PTGS1PTGS2ACKR3 | |
| SCHEMBL3124317 | 0.84 | MAOB (0.43) | CES2CES1PTGS1MAPTNPC1 | |
| SCHEMBL3124324 | 0.84 | MAOB (0.43) | CES2CES1PTGS1MAPTNPC1 | |
| SCHEMBL3769276 | 0.84 | CES2 (0.40) | CES2CES1PTGS1NFE2L2NPC1 | |
| SCHEMBL3769281 | 0.84 | CES2 (0.40) | CES2CES1PTGS1NFE2L2NPC1 | |
| SCHEMBL3770118 | 0.83 | NFE2L2 (0.45) | CES2CES1PTGS1PTGS2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | CES2 295/4885CES1 739/4885PTGS1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.